OPUS Biotech Communications Clients in the News
- Genetic Engineering News: Gene Therapy for Crigler-Najjar Syndrome, a Rare Liver Disease, Shows Efficacy
- Pharmaceutical Technology: UTMB and HDT Bio receive US funding for vaccine development
- Genetic Engineering News: Généthon and Thales Collaborate on AI Tools for Gene Therapy
- Clinical Trials Arena: HIghField Bio Initiates Its Glioma Trial with First Patient Dosing
- Genetic Engineering News: Lifesaving Gene Therapies: Will They Reach Those Who Need Them Most?
- Fierce Pharma: Atom Bioscience Hope to Make a Big Bang with New Gout Awareness Campaign
- Genetic Engineering News: Cystic Fibrosis Foundation Funds Nanoparticle Delivery to Lung
- Clinical Trials Arena: Atom Bioscience reports positive Phase IIa chronic gout therapy trial data
- Genethon Newsletter No. 1 : 2023
- Genetic Engineering News: Microalgal Vesicles Deliver Therapeutics to Protected Tissues
- Genetic Engineering News: Microalgal Vessicles Deliver Therapeutics to Protected Tissues
- GeekWire: Seattle Startup HDT Bio Lands $1.8M US Army Grant to Develop Nasal Spray Against Viruses
- Pharmaceutical Technology: HDT Bio receives Emergency Use Approval for Covid-19 Vaccine in India
- New York Times: Here’s Why Developing Countries Can Make MRNA Covid Vaccines
- Ophthalmology Times: Optogenetic Gene Therapy Restores Vision in 11 RP Patients
- BioWorld: Kineta Crafting Seaworthy RIG in Cancer after Merck Sets Sail with German Buy.
- Ovarian Cancer News: First Patient Enrolled in NanoPac Trial Evaluating New Anti-Cancer Treatment Delivery
- Practical Dermatology: Update from DFB Soria on Enrollment in Phase 2 Clinical Trial of Nanoparticle Paclitaxel Ointment for AK
- Cancer Treatment: DFB Pharmaceuticals forms new company that could revolutionize cancer treatment
- BioWorld: ‘Bare’-ish on naked effort, Nanology unveils particle approach across cancers.
- Inside Perspectives: Gene Editing Takes Center Stage
- WXPress: Will Immunotherapy Knock Out Cancer?
- Inside Perspectives: Will Immunotherapy Knock Out Cancer?
- Inside Perspectives on Cancer Immunotherapy: An Interview with TCR2 Therapeutics CEO Garry Menzel
- Gut Instinct: Leveraging the Microbiome and Human Immune System to Dramatically Transform Medicine
- Inside Perspectives on Cancer Immunotherapy: An Interview with Kineta’s Shawn Iadonato
- Improving the Odds in Cancer With First-Time Immunotherapies
- Inside Perspectives on Immunotherapy: An Interview with Advaxis CEO Daniel O’Connor
